Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FTLF FitLife Brands	$16.61 +2.8%	$13.73	$9.83 ▼ $17.75	$151.67M	0.79	21,789 shs	13,619 shs
MEIP MEI Pharma	$4.89 -0.2%	$3.81	$1.46 ▼ $9.00	$158.60M	0.37	3.24 million shs	565,430 shs
SLS SELLAS Life Sciences Group	$1.63 +5.2%	$1.77	$0.77 ▼ $2.27	$163.21M	2.26	1.82 million shs	1.30 million shs
SNTI Senti Biosciences	$1.52 -0.7%	$2.07	$1.46 ▼ $16.94	$40.03M	2.07	145,397 shs	73,302 shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FTLF FitLife Brands	+2.85%	+14.39%	+26.70%	+21.77%	+9.28%
MEIP MEI Pharma	-0.20%	-5.78%	+26.68%	+135.10%	+44.25%
SLS SELLAS Life Sciences Group	+5.16%	+3.16%	-15.10%	0.00%	+35.83%
SNTI Senti Biosciences	-0.65%	-3.80%	-22.84%	-52.20%	-29.95%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
FTLF FitLife Brands	4.1367 of 5 stars	3.5	4.0	0.0	2.6	1.7	3.1
MEIP MEI Pharma	2.167 of 5 stars	0.0	2.0	4.2	3.9	0.8	1.3
SLS SELLAS Life Sciences Group	2.7392 of 5 stars	3.5	2.0	0.0	3.4	1.7	0.6
SNTI Senti Biosciences	2.7409 of 5 stars	3.5	5.0	0.0	2.0	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FTLF FitLife Brands	3.00	Buy	$22.00	32.45% Upside
MEIP MEI Pharma	0.00	N/A	N/A	N/A
SLS SELLAS Life Sciences Group	3.00	Buy	$7.00	329.45% Upside
SNTI Senti Biosciences	3.00	Buy	$8.50	459.21% Upside

Current Analyst Ratings Breakdown

Latest SNTI, SLS, FTLF, and MEIP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/15/2025	FTLF FitLife Brands	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$20.00 ➝ $25.00
8/8/2025	SNTI Senti Biosciences	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00
7/16/2025	SLS SELLAS Life Sciences Group	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$4.00 ➝ $7.00
6/12/2025	SNTI Senti Biosciences	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00
6/6/2025	SNTI Senti Biosciences	Laidlaw Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$5.00

(Data available from 8/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FTLF FitLife Brands	$64.47M	2.42	$1.04 per share	15.94	$3.93 per share	4.23
MEIP MEI Pharma	$65.30M	2.42	$5.96 per share	0.82	$4.96 per share	0.99
SLS SELLAS Life Sciences Group	$1M	171.64	N/A	N/A	$0.25 per share	6.52
SNTI Senti Biosciences	$2.56M	15.53	N/A	N/A	$0.94 per share	1.62

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FTLF FitLife Brands	$8.98M	$0.84	19.77	15.10	N/A	12.63%	22.38%	13.63%	N/A
MEIP MEI Pharma	$17.78M	-$4.75	N/A	N/A	N/A	N/A	-77.00%	-64.79%	9/18/2025 (Estimated)
SLS SELLAS Life Sciences Group	-$30.88M	-$0.32	N/A	N/A	N/A	N/A	-132.51%	-92.79%	N/A
SNTI Senti Biosciences	-$52.79M	-$8.95	N/A	N/A	N/A	N/A	-223.98%	-76.02%	N/A

Latest SNTI, SLS, FTLF, and MEIP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	FTLF FitLife Brands	$0.18	$0.18	N/A	$0.18	$16.17 million	$16.13 million
8/12/2025	Q2 2025	SLS SELLAS Life Sciences Group	-$0.0767	-$0.07	+$0.0067	-$0.07	N/A	N/A
8/7/2025	Q2 2025	SNTI Senti Biosciences	-$0.58	-$0.56	+$0.02	-$0.56	$1.30 million	$0.50 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
FTLF FitLife Brands	N/A	N/A	N/A	N/A	N/A
MEIP MEI Pharma	N/A	N/A	N/A	N/A	N/A
SLS SELLAS Life Sciences Group	N/A	N/A	N/A	N/A	N/A
SNTI Senti Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FTLF FitLife Brands	0.19	1.64	0.72
MEIP MEI Pharma	N/A	16.78	16.78
SLS SELLAS Life Sciences Group	N/A	4.91	4.64
SNTI Senti Biosciences	N/A	3.26	4.22

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FTLF FitLife Brands	2.32%
MEIP MEI Pharma	52.38%
SLS SELLAS Life Sciences Group	17.38%
SNTI Senti Biosciences	25.73%

Insider Ownership

Company	Insider Ownership
FTLF FitLife Brands	61.40%
MEIP MEI Pharma	3.12%
SLS SELLAS Life Sciences Group	1.40%
SNTI Senti Biosciences	3.12%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FTLF FitLife Brands	20	9.39 million	3.63 million	Not Optionable
MEIP MEI Pharma	100	32.37 million	31.36 million	Optionable
SLS SELLAS Life Sciences Group	10	105.30 million	103.82 million	Not Optionable
SNTI Senti Biosciences	4	26.16 million	25.34 million	Not Optionable

SNTI, SLS, FTLF, and MEIP Headlines

Recent News About These Companies

Chardan Capital Issues Optimistic Forecast for SNTI Earnings

August 15 at 2:52 AM | americanbankingnews.com

Senti Biosciences to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

August 14 at 9:15 AM | globenewswire.com

Senti Biosciences Discusses Phase 2 Dose Selection for SENTI-202 in Virtual Investor Segment

August 12, 2025 | quiverquant.comQ

Senti Bio Participates in Virtual Investor “What This Means” Segment Discussing The Phase 2 Dose and Schedule Selection for SENTI-202 in its Clinical Trial for Acute Myeloid Leukemia

August 12, 2025 | globenewswire.com

Senti Biosciences' (SNTI) Buy Rating Reiterated at Chardan Capital

August 11, 2025 | americanbankingnews.com

Senti Biosciences, Inc.: Senti Bio Reports Second Quarter 2025 Financial Results and Confirms Next Data Milestone for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML ...

August 8, 2025 | finanznachrichten.de

Senti Bio Reports Second Quarter 2025 Financial Results and Confirms Next Data Milestone for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) Expected Q4 2025

August 7, 2025 | globenewswire.com

Senti Bio Determines Recommended Phase 2 Dose (RP2D) in Phase 1 Study of SENTI-202 for the Treatment of Relapsed/Refractory Hematologic Malignancies, Including Acute Myeloid Leukemia

August 5, 2025 | globenewswire.com $https://www.globenewswire.com/news-release/2025/08/05/3127362/0/en/senti-bio-determines-recommended-phase-2-dose-rp2d-in-phase-1-study-of-senti-202-for-the-treatment-of-relapsed-refractory-hematologic-malignancies-including-acute-myeloid-leukemia.html$

Senti Biosciences Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference

July 23, 2025 | finance.yahoo.com

Senti Biosciences Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

July 22, 2025 | globenewswire.com

Senti Bio's Chief Medical Officer, Kanya Rajangam, M.D., Ph.D. to Give Feature Presentation at the BioScience Forum

July 21, 2025 | globenewswire.com

Senti Biosciences, Inc. Appoints Bryan Baum to Board of Directors

July 18, 2025 | quiverquant.comQ

Senti Bio Appoints Entrepreneurial Leader and Investor, Bryan Baum, to Board of Directors

July 18, 2025 | globenewswire.com

NASDAQ:SNTI Financials | Senti Biosciences Inc - Investing.com

July 3, 2025 | investing.com

SNTI - Senti Biosciences Inc Sustainability - Morningstar

July 2, 2025 | morningstar.comM

Senti Biosciences CEO Timothy Lu Highlights Advancements in Gene Circuit Technology at Nasdaq’s Amplify Spotlight Series

June 30, 2025 | quiverquant.comQ

Senti Bio Participates in Nasdaq Amplify Spotlight Series

June 30, 2025 | globenewswire.com

Senti Biosciences, Inc. to Present at 2025 SEED Conference on Tumor-Specific Therapies - Nasdaq

June 26, 2025 | nasdaq.com

Senti Biosciences, Inc. to Present at 2025 SEED Conference on Tumor-Specific Therapies

June 24, 2025 | quiverquant.comQ

Senti Bio to Present at the 2025 Synthetic Biology: Engineering, Evolution, & Design (SEED) Conference

June 24, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNTI, SLS, FTLF, and MEIP Company Descriptions

FitLife Brands NASDAQ:FTLF

$16.61 +0.46 (+2.85%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$16.60 0.00 (-0.03%)

As of 08/15/2025 04:10 PM Eastern

FitLife Brands, Inc. provides nutritional supplements for health-conscious consumers in the United States and internationally. The company provides weight loss, sports nutrition, and general health products; sports nutrition products; weight loss and sports nutrition products; sports nutrition and general wellness formulations with an emphasis on natural, vegan, and organic ingredients; and male health and weight loss products, as well as other diet, health, and sports nutrition supplements and related products; and value-oriented sports nutrition and weight loss products. It offers MRC products which includes general health supplements; and natural skincare and beauty products. In addition, it markets its products under the brand names of NDS Nutrition, PMD Sports, SirenLabs, CoreActive, Nutrology, Metis Nutrition, iSatori, BioGenetic Laboratories, Energize, Dr. Tobias, All-Natural Advice, and Maritime Naturals through franchised stores, as well as through retail locations, which include specialty, mass, and online. The company was formerly known as Bond Laboratories, Inc. and changed its name to FitLife Brands, Inc. in September 2013. FitLife Brands, Inc. was incorporated in 2005 and is headquartered in Omaha, Nebraska.

MEI Pharma NASDAQ:MEIP

$4.89 -0.01 (-0.20%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$4.93 +0.04 (+0.92%)

As of 08/15/2025 07:55 PM Eastern

MEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex which has completed Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer. MEI Pharma, Inc. has a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.

SELLAS Life Sciences Group NASDAQ:SLS

$1.63 +0.08 (+5.16%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$1.64 +0.01 (+0.31%)

As of 08/15/2025 07:58 PM Eastern

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

Senti Biosciences NASDAQ:SNTI

$1.52 -0.01 (-0.65%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$1.56 +0.04 (+2.89%)

As of 08/15/2025 07:58 PM Eastern

Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time